Su-11652

Su-11652

SCHEMBL2212420

CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(Cl)cc32)c1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 15/20 1.00
PDGFRB P09619 5/20 1.00
FGFR1 P11362 4/20 1.00
EGFR P00533 3/20 1.00
KIT P10721 2/20 1.00
NEK2 P51955 2/20 1.00
MELK Q14680 2/20 1.00
PRKAA1 Q13131 14/20 0.87
PRKAA2 P54646 13/20 0.87
FLT3 P36888 4/20 0.81
PLK4 O00444 2/20 0.81
DCLK1 O15075 2/20 0.81
PDPK1 O15530 2/20 0.81
DAPK3 O43293 2/20 0.81
ROCK2 O75116 2/20 0.81
RPS6KA5 O75582 2/20 0.81
RPS6KA4 O75676 2/20 0.81
MAP4K4 O95819 2/20 0.81
CHEK2 O96017 2/20 0.81
NTRK1 P04629 2/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Su-11652 SCHEMBL2114096 1.00 KDR (1.00) KDRPDGFRBFGFR1EGFRKIT
Su-11652 SCHEMBL21067494 1.00 KDR (1.00) KDRPDGFRBFGFR1EGFRKIT
Su-11652 SCHEMBL29366350 1.00 KDR (1.00) KDRPDGFRBFGFR1EGFRKIT
SCHEMBL29857040 0.93 PRKAA1 (1.00) KDRPDGFRBFGFR1EGFRKIT
SCHEMBL31672439 0.91 KDR (0.84) KDRPDGFRBFGFR1EGFRKIT
SCHEMBL15202704 0.91 KDR (0.84) KDRPDGFRBFGFR1EGFRKIT
SCHEMBL2113942 0.91 KDR (0.84) KDRPDGFRBFGFR1EGFRKIT
SCHEMBL13755223 0.91 KDR (0.84) KDRPDGFRBFGFR1EGFRKIT
SCHEMBL22486002 0.90 KDR (0.82) KDRPDGFRBFGFR1EGFRKIT
SCHEMBL18651190 0.90 KDR (0.85) KDRPDGFRBFGFR1EGFRKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180153902-A1 SMALL MOLECULE SCREENING FOR MOUSE SATELLITE CELL PROLIFERATION HOWARD HUGHES MEDICAL INSTITUTE 2018-06-07 US disclosed
US-9782417-B2 Methods of increasing satellite cell proliferation with kinase inhibitors PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) 2017-10-10 US disclosed
US-20160220580-A1 SMALL MOLECULE SCREENING FOR MOUSE SATELLITE CELL PROLIFERATION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-08-04 US disclosed
US-9248185-B2 Methods of increasing satellite cell proliferation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2016-02-02 US disclosed
US-20140294855-A1 SMALL MOLECULE SCREENING FOR MOUSE SATELLITE CELL PROLIFERATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-10-02 US disclosed
US-20110262465-A1 PROSTATE STEM CELLS AND USES THEREOF GENENTECH, INC. (US) 2011-10-27 US disclosed
EP-2342225-A1 PROSTATE STEM CELLS AND USES THEREOF F. Hoffmann-La Roche AG (CH) 2011-07-13 EP disclosed
WO-2010048278-A1 PROSTATE STEM CELLS AND USES THEREOF GENENTECH, INC. (US) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180153902-A1 SMALL MOLECULE SCREENING FOR MOUSE SATELLITE CELL PROLIFERATION MKI67, MYLK2, MYH2 KDR 2498/4885PDGFRB 469/4885FGFR1 624/4885
US-20140294855-A1 SMALL MOLECULE SCREENING FOR MOUSE SATELLITE CELL PROLIFERATION MKI67, MYLK2, MYH2 KDR 2640/4885PDGFRB 465/4885FGFR1 577/4885
US-20160220580-A1 SMALL MOLECULE SCREENING FOR MOUSE SATELLITE CELL PROLIFERATION MKI67, MYLK2, MYH2 KDR 2498/4885PDGFRB 469/4885FGFR1 624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.